Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Saturday, 28'th Jun 2025
NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investor
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
06:51pm, Friday, 27'th Jun 2025
In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.
Gilead shares rise after US top court ruling on preventative coverage
10:59am, Friday, 27'th Jun 2025
Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare law that helps guarantee that health insurers cover preventive care at no cost to patien
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 27'th Jun 2025
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Friday, 27'th Jun 2025
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advise
Gilead partners with Kymera to develop novel cancer therapy
11:41am, Wednesday, 25'th Jun 2025
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cy
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
09:15am, Wednesday, 25'th Jun 2025
Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive opt
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
08:00am, Tuesday, 24'th Jun 2025
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered di
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
12:17pm, Monday, 23'rd Jun 2025
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investor
Gilead Sciences CEO Daniel O'Day on HIV prevention injection approval
10:54am, Monday, 23'rd Jun 2025
Gilead Sciences CEO Daniel O'Day explains why he believes the biopharma's HIV prevention injection Yeztugo, which received approval from the Food and Drug Administration last week, is a "milestone mom
Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
09:31am, Monday, 23'rd Jun 2025
Gilead Sciences chairman and CEO Daniel O'Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Sunday, 22'nd Jun 2025
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised
4 BofA Securities Strong Buy Growth 10 Stocks Also Pay Reliable Dividends
07:45am, Saturday, 21'st Jun 2025
Investors love growth stocks that also pay big and reliable dividends because they provide dependable passive income streams and an excellent opportunity for solid total return.
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
02:31pm, Thursday, 19'th Jun 2025
GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.
